378 members of Congress urge House leaders to continue funding special diabetes research program
WASHINGTON, D.C. – It’s hard to get 378 members of Congress to agree on almost anything these days, but continuing to fund a special diabetes research program that’s working to find a cure to the disease seems to be one of the few things that nearly every member of the U.S. House is willing to support.
A bipartisan group of 378 lawmakers in the House of Representatives sent a letter today to Speaker of the House Nancy Pelosi and Republican Leader Kevin McCarthy urging them to continue funding a pair of special diabetes research programs that currently provide $150 million a year in federal funds to research new ways to treat and prevent the disease.
The letter, led by U.S. Reps. Diana DeGette (D-CO) and Tom Reed (R-NY), the co-chairs of the Congressional Diabetes Caucus, comes as the two programs – the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians – are set to expire at the end of September, if Congress fails to act.
“The [Special Diabetes Program] is making meaningful progress,” the lawmakers wrote. “However, further investment in these vital programs is essential to continue outreach and education, plan next steps for research programs, and effectively allocate resources – all of which play an important role in helping to better treat, prevent, and ultimately cure diabetes.”
Congress first established the two programs in 1997 after a bipartisan Congressional Diabetes Research Working Group found serious limitations in the nation’s ability to research and treat the disease due, in large part, to a lack of funding.
The Special Diabetes Program for Type 1 Diabetes was established to provide funding to the National Institutes of Health to study type 1 diabetes, while the Special Diabetes Program for Indians was set up to provide funding to Indian Health Services to help prevent and treat type 2 diabetes among American Indians and Alaska Natives.
Both programs remain in existence today and each currently receives $150 million a year in federal funding.
Since it was first established, the special diabetes program for Type 1 research has contributed more than $2.7 billion towards diabetes research. That funding has already resulted in several significant breakthroughs and discoveries, and has helped to develop many new treatments now available to patients.
In urging the leaders to continue supporting both programs, the lawmakers specifically point to their success in helping to develop the first fully automated insulin-dosing system that’s now available to patients, discovering a new way to actually reverse vision loss in some people living with diabetes, as well as, the positive impact it’s having on the overall health of American Indians and Alaskan natives.
In addition to the program’s many successes, the lawmakers point out that continuing to fund the two programs is important not only for the 114 million Americans living with or at risk of developing diabetes, but also for the nation’s overall economy.
Right now, approximately one out of every four dollars spent on health care in the U.S. – and one out of every three dollars spent by Medicare – is spent treating people with diabetes.
Until researchers find a way to prevent or cure the disease, those numbers are expected to rise even further as an additional 1.5 million Americans are expected to be diagnosed with the disease every year.
The lawmakers’ call for continued support of the program drew quick praise from some of the nation’s leading diabetes advocacy organizations.
“We knew the Special Diabetes Program had tremendous bipartisan backing, but ADA is truly astounded and encouraged to see 378 members of Congress join the letter that the Co-Chairs of the Congressional Diabetes Caucus, Representatives Diana DeGette and Tom Reed, circulated,” said Dr. LaShawn McIver, with the American Diabetes Association. “SDP has had measurable outcomes on both the research side and the American Indian/Alaska Native programming component. Without the funding provided by the Special Diabetes Program, we would not have the first artificial pancreas system or the more than 50% reduction in end stage kidney disease in AI/AN communities.”
“JDRF and our countless volunteers sincerely thank Representatives Diana DeGette and Tom Reed, the Co-Chairs of the Congressional Diabetes Caucus, for their tremendous continued leadership and support of the Special Diabetes Program,” said Aaron J. Kowalski, president of the Juvenile Diabetes Research Foundation. “Research funded by this program is accelerating our understanding of type 1 diabetes, developing new treatments and therapies that will continue to significantly improve the lives of those impacted by T1D, and bringing us steps closer to our ultimate goal of a cure.”
Following is the full text of the lawmakers’ letter to House leaders, while a PDF copy showing the full list of cosigners is available here:
May 9, 2019
The Honorable Nancy Pelosi
Speaker of the House
United States House of Representatives
H-232, The Capitol
Washington, D.C. 20515
The Honorable Kevin McCarthy
House Republican Leader
United States House of Representatives
H-204, The Capitol
Washington, D.C. 20515
Dear Speaker Pelosi and Republican Leader McCarthy:
We write today to thank you for your strong and steadfast support of the Special Diabetes Program and ask for your commitment to reauthorize the program prior to the expiration of its current authorization in September 2019. The Special Diabetes Program is comprised of two important components: the Special Statutory Funding Program for Type 1 Diabetes Research (SDP) and the Special Diabetes Program for Indians (SDPI). Without question, the lives of roughly 30.3 million individuals with diabetes, 84.1 million with prediabetes, and countless families impacted by the disease have benefited from these critical programs. It is essential that we continue to invest in the research necessary to develop a cure for diabetes, as well as support the programs that help prevent and treat the disease and its complications.
Diabetes is our country’s most costly disease in both human and economic terms, affecting people of all ages, races, and in every region of our country. It is the number one cause of kidney disease, blindness in working-age adults, and lower-limb amputations. In addition, it is a leading cause of heart disease and stroke. Approximately one in four health care dollars and one in three Medicare dollars are spent treating people with diabetes. The total cost of diagnosed diabetes in the United States in 2017 was $327 billion, with $237 billion for direct medical costs and another $90 billion due to reduced productivity. Medical expenditures for individuals diagnosed with diabetes are roughly 2.3 times higher than expenditures for those without the disease.
Overall, the economic costs of diabetes, adjusted for inflation, increased by 26 percent from 2012 to 2017, and these costs are expected to increase as the number of people with diabetes continues to grow. According to the Centers for Disease Control and Prevention’s 2017 National Diabetes Statistics Report, an estimated 1.5 million new cases of diabetes (6.7 per 1,000 persons) were diagnosed among U.S. adults in 2015.
While the increase in these statistics is very concerning, the SDP is making meaningful progress. SDP funds research that is leading directly to the development of new insights and therapies that are improving the lives of those with diabetes and accelerating progress towards curing and preventing the disease. Likewise, the SDPI is having a significant and positive impact on the health of American Indians and Alaska Natives (AI/AN), who are disproportionately affected by type 2 diabetes. The SDPI is making it possible to develop and sustain quality diabetes treatment and prevention programs in AI/AN communities where they are most needed.
Some notable developments from SDP and SDPI include:
Artificial Pancreas (AP) Systems: SDP-funded research greatly accelerated the development of AP systems, which have shown the ability to reduce costly and burdensome type 1 diabetes (T1D) complications and improve the quality of life for those with the disease. SDP funds led to the first fully automated insulin-dosing system being made available to patients in 2017, some 5 to 7 years earlier than expected. Multiple other AP systems are being tested in outpatient trials. According to one study, the use of AP systems in adults could save Medicare roughly $1 billion over 25 years.
Kidney Disease: Researchers have discovered that 6.5 years of intensive blood glucose control can cut in half the onset of impaired kidney function in people with T1D. This reduction in end-stage renal disease could save Medicare roughly $126 billion over 25 years. Kidney disease in AI/AN individuals is also in decline. Between 1996 and 2013, incidence rates of end-stage renal disease (ESRD) in AI/AN individuals with diabetes declined by 54 percent. The decrease in ESRD incidence has resulted in a 29 percent decrease in prevalence of ESRD since 2000, representing the only instance of a decline in adjusted prevalence for a major racial group.
Eye Therapies: SDP-funded research discovered that combining a drug with laser therapy can reverse vision loss in people living with diabetes. The SDP also filled a critical research gap by funding a head-to-head comparison of three drugs for the treatment of diabetic eye disease. The results are helping patients, clinicians, and insurers to identify the right therapy and course of treatment for each individual person. During the SDP era, diabetic eye disease rates have decreased by 50 percent for AI/ANs, resulting in a reduction of vision loss and blindness among AI/AN patients.
Prevention: A truly groundbreaking 15-year study of 8,600 children is currently ongoing to determine what environmental factors influence the onset of T1D. Researchers believe that by identifying specific triggering factors, new strategies can be developed to prevent the initial onset of the disease. Communities with SDPI-funded programs have seen a 54 percent increase in nutrition services, a 72 percent increase in community walking and running programs, a 59 percent increase in adult weight management programs, and a 56 percent increase in weight management for children and youth.
Glucose Control: The average blood sugar level, as measured by the hemoglobin A1C test, decreased from 9.0 percent in 1996 to 8.1 percent in 2014 in the AI/AN population. Every percentage point drop in A1C can reduce the risk of eye, kidney, and nerve complications by up to 40 percent.
Clearly, the SDP and SDPI are improving the lives of the over 114 million Americans living with or at risk of developing diabetes, while also greatly reducing the long-term health care expenditures related to its complications. However, further investment in these vital programs is essential to continue outreach and education, plan next steps for research programs, and effectively allocate resources – all of which play an important role in helping to better treat, prevent, and ultimately cure diabetes.
Thanks to your leadership, both components of the Special Diabetes Program continue to receive strong bipartisan support. We look forward to working with you to ensure that these programs together remain a beacon of hope for all Americans living with or at risk of diabetes.